PTCT250117P34000
- 0.00
- 0.000.00%
PTC Therapeutics Newsroom
RBC Capital Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $60
Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT), COMPASS Pathways (CMPS) and Cogstate Ltd (OtherCOGZF)
Leerink Partners Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Announces Target Price $45
PTC Therapeutics (PTCT) Receives a Hold From Leerink Partners
Cantor Fitzgerald Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $76
Cantor Fitzgerald Sticks to Its Buy Rating for PTC Therapeutics (PTCT)
Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Lowers Price Target to $76
PTC Therapeutics Analyst Ratings
Citi Maintains PTC Therapeutics(PTCT.US) With Sell Rating, Maintains Target Price $32
BofA Securities Maintains PTC Therapeutics(PTCT.US) With Sell Rating, Maintains Target Price $41
TD Cowen Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Maintains Target Price $46
A Quick Look at Today's Ratings for PTC Therapeutics(PTCT.US), With a Forecast Between $41 to $67
PTC Therapeutics (PTCT) Gets a Sell From Bank of America Securities
RBC Capital Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Cuts Target Price to $58
RBC Cuts Price Target on PTC Therapeutics to $58 From $63, Keeps Outperform Rating
PTC Therapeutics Raised to Overweight From Equal-Weight by Morgan Stanley
PTC Therapeutics Price Target Raised to $67.00/Share From $45.00 by Morgan Stanley
PTC Therapeutics Analyst Ratings
RBC Capital Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $63
PTC Therapeutics (PTCT) Receives a Buy From RBC Capital